¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"glyco"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycolyl
    ±Û¸®Äݸ±-, ±Û¸®Äݸ±±â
  • glycolysis
    ÇØ´çÀÛ¿ë
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò
  • glycolytic ferment
    ´çºÐÇØÈ¿¼Ò, ÇØ´ç¹ßÈ¿¼Ò
  • glycometabolism
    ´ç´ë»ç
  • glyconeogenesis
    ´ç½Å»ý
  • glyconucleoprotein
    ´çÇٴܹé
  • glycopenia
    Àú´çÁõ
  • glycopexis
    Àú´ç, ´ç°íÁ¤
  • glycophorin
    ±Û¸®ÄÚÆ÷¸°
  • glycophospholipin
    ´çÀÎÁöÁú
  • glycopolyuria
    ´ç´Ù´¢Áõ
  • glycoprotein
    ´ç´Ü¹éÁú
  • glycoptyalism
    ´ÜħÁõ, ´çŸ¾×Áõ
  • glycorrhachia
    ´ç³úô¼ö¾×Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycolipid
    ´çÁöÁú
  • glycolyl
    ±Û¸®Äݸ±±â
  • glycolysis
    ÇØ´çÀÛ¿ë
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò
  • glycolytic ferment
    ÇØ´ç¹ßÈ¿¼Ò, ´ç¿ëÇØ¹ßÈ¿¼Ò
  • glycometabolism
    ´ç´ë»ç
  • glyconeogenesis
    ´ç½Å»ý
  • glyconucleoprotein
    ´çÇٴܹé
  • glycopenia
    Àú´çÁõ
  • glycopexis
    Àú´ç, ´ç°íÁ¤
  • glycophorin
    ±Û¸®ÄÚÆ÷¸°
  • glycophospholipin
    ´çÀÎÁöÁú
  • glycopolyuria
    ´ç´Ù´¢Áõ
  • glycoprotein
    ´ç´Ü¹éÁú
  • glycoptyalism
    (¢¡glycosialia) ´ÜħÁõ, ´çŸ¾×Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • Glycogen synthase
    ±Û¸®ÄÚ°ÕÇÕ¼º(ùêà÷)
  • glycogen synthase
    ´ç¿ø ÇÕ¼ºÈ¿¼Ò
  • Glycogen-lactic acid system
    ±Û¸®ÄÚ°Õ-¶ôÆ®»ê°è
  • glycogenase
    ±Û¸®ÄÚ°ÕºÐÇØÈ¿¼Ò, ±Û¸®ÄÚ°Ô ³ªÁ¦.
  • Glycogenesis
    ±Û¸®ÄÚ°ÕÇÕ¼º(ùêà÷)
  • glycogenesis
    ±Û¸®ÄÚ°ÕÇÕ¼º(¡­ùêà÷).
  • glycogenic
    ´ç»ý¼º(ÓØßæà÷)(ÀÇ).
  • glycogenic cardiomegalia
    ±Û¸®ÄڰհŽÉÁõ(¡­ËÝãýñø).
  • glycogenic infiltration
    ±Û¸®ÄÚ°ÕħÀ±.
  • Glycogenolysis
    ´ç¿øºÐÇØ(ÓØê«ÝÂú°), ±Û¸®ÄÚ°ÕºÐÇØ(ÝÂú°)
  • glycogenolysis
    ´ç¿øºÐÇØ(ÓØê«ÝÂú°), ±Û¸®ÄÚ°ÕºÐÇØ(ÝÂú°).
  • glycogenolysis
    ´ç¿øºÐÇØ, ±Û¶óÀÌÄÚÀüºÐÇØ.
  • glycogenoses
    ´ç¿øÃàÀûÁõ, ´ç¿øº´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycogen synthase
    ´ç¿ø ÇÕ¼ºÈ¿¼Ò
  • glycogenase
    ±Û¸®ÄÚ°ÕºÐÇØÈ¿¼Ò, ±Û¸®ÄÚ°Ô ³ªÁ¦.
  • glycogenesis
    ±Û¸®ÄÚ°ÕÇÕ¼º(¡­ùêà÷).
  • glycogenic
    ´ç»ý¼º(ÓØßæà÷)(ÀÇ).
  • glycogenic cardiomegalia
    ±Û¸®ÄڰհŽÉÁõ(¡­ËÝãýñø).
  • glycogenic infiltration
    ±Û¸®ÄÚ°ÕħÀ±.
  • glycogenolysis
    ´ç¿øºÐÇØ, ±Û¶óÀÌÄÚÀüºÐÇØ.
  • glycogenolysis
    ´ç¿øºÐÇØ(ÓØê«ÝÂú°), ±Û¸®ÄÚ°ÕºÐÇØ(ÝÂú°).
  • glycogenoses
    ´ç¿øÃàÀûÁõ, ´ç¿øº´
  • glycogenosis
    ´ç¿øÃàÀûÁõ
  • glycogenosis
    ´ç¿øÃàÀûÁõ(ÓØê«õëîÝñø), ±Û¸®ÄÚ°Õ
  • glycogenosis
    ´ç¿øÃàÀûÁõ(ÓØê«õëîÝñø), ±Û¸®ÄÚ°ÕÁõ
  • glycogenosis circumscripta
    ±¹ÇѼº ±Û¸®ÄÚ°ÕÁõ.
  • glycogenosis universalis
    ¹ü¹ß¼º ±Û¸®ÄÚ°ÕÁõ.
  • glycoglycinuria
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glycogenosis
    "±Û¶óÀÌÄÚÀü(ÃàÀû,õëîÝ)Áõ(ñø)"
  • glycoglycerolipid
    ±Û¸®¼¼·Ñ´çÁöÁú(ÓØò·òõ)
  • glycol
    ±Û¶óÀÌÄÝ
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolic acid cycle
    ±Û¶óÀÌÄÝ»ê(ß«) ȸ·Î(üÞÖØ)
  • glycolipid
    ±Û¶óÀÌÄÚÁöÁú(ò·òõ)
  • glycoloyl group
    ±Û¶óÀÌÄÚ·ÎÀϱâ(Ðñ)
  • glycolyl group
    ±Û¶óÀÌÄÚ¸±±â(Ðñ)
  • glycolysis
    ´çºÐÇØ(ÓØÝÂú°)
  • glycolytic flux
    ´çºÐÇØ(ÓØÝÂú°) Çöô½º
  • glycolytic pathway
    ´çºÐÇØ °æ·Î(ÓØÝÂú°ÌèÖØ)
  • glycone
    ±Û¶óÀÌÄÜ
  • glyconeogenesis
    ±Û¶óÀÌÄÚÀü ½Å»ý(ãæßæ)
  • glyconic acid
    ´ç»ê(ÓØß«)
  • glycopeptide
    ´çÆéŸÀ̵å
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glycogelatin A preparation made of equal parts of gelatin and glycerin; a firm mass liquefying at gentle heat; it is used as a vehicle for suppositories and urethral bougies.
Synonym: glycerin jelly, glycerogelatin, glycogelatin.
(05 Mar 2000)
glycogen <biochemistry> Branched polymer of D glucose (mostly _(1-4) linked, but some _(1-6) at branch points).
Size range very variable, up to 10exp5 glucose units. Major short term storage polymer of animal cells and is particularly abundant in the liver and to a lesser extent in muscle. In the electron microscope glycogen has a characteristic asterisk or star appearance.
(18 Nov 1997)
glycogen debranching enzyme system 1,4-alpha-d-glucan-1,4-alpha-d-glucan 4-alpha-d-glucosyltransferase/dextrin 6 alpha-d-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (ec 2.4.1.25) and amylo-1,6-glucosidase (ec 3.2.1.33) activities. As a transferase it transfers a segment of a 1,4-alpha-d-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-d-glucan. As a glucosidase it catalyses the endohydrolysis of 1,6-alpha-d-glucoside linkages at points of branching in chains of 1,4-linked alpha-d-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III.
(12 Dec 1998)
glycogen granule Glycogen occurring in cells as beta granule's which average about 300 A
glycogen phosphorylase <enzyme> Enzyme that catalyses the sequential removal of glycosyl residues from glycogen to yield one glucose-1-phosphate per reaction. Its activity is controlled by phosphorylation (by phosphorylase kinase).
(21 Jun 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
glycogen synthase <enzyme> An enzyme of the transferase class that catalyses the reaction of udpglucose and (1,4-alpha-d-glucosyl)n to yield udp and 1,4-alpha-d-glucosyl)n+1. The reaction is highly regulated by allosteric effectors, by phosphorylation reactions, and by insulin.
Chemical name: UDPglucose:glycogen 4-alpha-D-glucosyltransferase
Registry number: EC 2.4.1.11
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 2
  • Glycogen - »õâ
    Synonyms :
  • Glycogen Debranching Enzyme System - »õâ 1,4-alpha-D-Glucan-1,4-alpha-D-glucan 4-alpha-D-glucosyltransferase/dextrin 6 alpha-D-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (EC 2.4.1.25) and amylo-1,6-glucosidase (EC 3.2.1.33) activities. As a transferase it transfers a segment of a 1,4-alpha-D-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-D-glucan. As a glucosidase it catalyzes the endohydrolysis of 1,6-alpha-D-glucoside linkages at points of branching in chains of 1,4-linked alpha-D-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III.
    Synonyms : Debranching Enzyme, Glycogen, Enzyme, Glycogen Debranching, Transfer Glucosidase
  • Glycogen Phosphorylase - »õâ An enzyme that catalyzes the degradation of GLYCOGEN in animals by releasing glucose-1-phosphate from the terminal alpha-1,4-glycosidic bond. This enzyme exists in two forms: an active phosphorylated form ( PHOSPHORYLASE A) and an inactive un-phosphorylated form (PHOSPHORYLASE B). Both a and b forms of phosphorylase exist as homodimers. In mammals, the major isozymes of glycogen phosphorylase are found in muscle, liver and brain tissue.
    Synonyms : Phosphorylase ab, Phosphorylase, Glycogen
  • Glycogen Phosphorylase, Brain Form - »õâ An isoenzyme of GLYCOGEN PHOSPHORYLASE that catalyzes the degradation of GLYCOGEN in brain tissue.
    Synonyms : Glycogen Phosphorylase a, Brain Form, Glycogen Phosphorylase b, Brain Form
  • Glycogen Phosphorylase, Liver Form - »õâ An isoenzyme of GLYCOGEN PHOSPHORYLASE that catalyzes the degradation of GLYCOGEN in liver tissue. Mutation of the gene coding this enzyme on chromosome 14 is the cause of GLYCOGEN STORAGE DISEASE TYPE VI.
    Synonyms : Glycogen Phosphorylase a, Liver Form, Glycogen Phosphorylase b, Liver Form
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 10 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¸í¹®¸ðºñ´­ÁÖ»ç2ml - »õâ
¸í¹®Á¦¾à
A31801181 Glycopyrrolate
Àü¹®ÀǾàǰ | »èÁ¦
µ¿±¹±Û¸®ÄÚÇÇ·Ñ·¹ÀÌÆ®ÁÖ»ç0.4mg(ÇÁ¸®Çʵå) - »õâ
µ¿±¹Á¦¾à
A00701171 Glycopyrrolate
Àü¹®ÀǾàǰ | ±Þ¿©
±×¸®ÄÚ¹ÎÁ¤250mg - »õâ
Àϼº½Å¾à
A11303261 Metformin HCl
Àü¹®ÀǾàǰ | »èÁ¦
±×¸®ÄÚ¹ÎÁ¤ - »õâ
Àϼº½Å¾à
A11303141 Metformin HCl
Àü¹®ÀǾàǰ | ±Þ¿©
Ÿ·ÎµòÁÖ»ç1ml - »õâ
È޿½º
A29551631 Glycopyrrolate
Àü¹®ÀǾàǰ | »èÁ¦
»ïõ´ç±Û¸®ÄÚÇÇ·Ñ·¹ÀÌÆ®ÁÖ0.2mg - »õâ
»ïõ´çÁ¦¾à
A08401641 Glycopyrrolate
Àü¹®ÀǾàǰ | ±Þ¿©
Á¦³ëŲ - »õâ
³ì½ÊÀÚ
Glycol Salicylate, Glycyrrhetic acid, L-menthol, Mentha oil, Nonylvanillamide
ÀϹÝÀǾàǰ | ¹Ì»ý»ê
ÄÚºñ³îÁÖ»ç - »õâ
ºñ¾¾¿ùµåÁ¦¾à
A16203021 Glycopyrrolate
Àü¹®ÀǾàǰ | »èÁ¦
³ë¹Ù·ÑÁÖ0.4mg - »õâ
Çѱ¹À¯³ªÀÌÆ¼µåÁ¦¾à
A12900781 Glycopyrrolate
Àü¹®ÀǾàǰ | »èÁ¦
ÁøÈ²ÆÄÇÁīŸÇö󽺸¶ - »õâ
Á¦ÀϾàǰ
Glycol Salicylate, L-menthol, Phellodendron bark soft extract, Tocopherol Acetate
ÀϹÝÀǾàǰ | ºñ±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 2 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
glycolysis a metabolic process that breaks down carbohydrates and sugars through a series of reactions to either pyruvic acid or lactic acid and release energy for the body in the form of ATP
Ãâó: wordnet.princeton.edu/perl/webwn
glycoprotein a conjugated protein having a carbohydrate component
Ãâó: wordnet.princeton.edu/perl/webwn
glycoside a group of compounds derived from monosaccharides
Ãâó: wordnet.princeton.edu/perl/webwn
glycosuria the presence of abnormally high levels of sugar in the urine
Ãâó: wordnet.princeton.edu/perl/webwn
glycogen infiltration abnormal accumulations of glycogen within the cytoplasm of cells, as occurs in diabetes mellitus and the glycogen storage diseases.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 2
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á